Investor Presentaiton

ENHERTU Development of HER2 low breast cancer Now conducting DESTINY-Breast06/08 studies in earlier lines of HER2 low breast cancer and further development is under discussion HR+/HER2 low BC Endocrine therapy + CDK4/6 inhibitor Chemotherapy 1L Chemotherapy 2L HR-/HER2 low BC Not Applicable BC: breast cancer, HR: hormone receptor DESTINY-Breast06 Ph3 DESTINY-Breast08 Ph1b, combination Daiichi-Sankyo Chemotherapy 3L DESTINY-Breast04 Ph3 DESTINY-Breast04 Ph3 DESTINY-Breast08 Ph1b, combination 20 10

View entire presentation